A bioactive composition based on cyclocurcumin, derived from turmeric, with improved stability and therapeutic efficacy.

Abstract

A cyclocurcumin-based composition comprising: cyclocurcumin in an amount of 25 to 40% by weight of the total composition; one or more residual curcuminoids, including curcumin and demethoxycurcumin, in a total amount of 8 to 18% by weight; an antioxidant stabilizer selected from ascorbic acid, tocopherol, or a combination thereof in an amount of 3 to 8% by weight; a bioavailability enhancer containing piperine in an amount of 1 to 3% by weight; and a pharmaceutically acceptable excipient in an amount of 40 to 60% by weight.

Description

AREA OF INVENTION The present invention relates to a bioactive phytochemical composition from turmeric, in particular a composition enriched with cyclocurcumin, formulated with defined proportions of the components to achieve improved biological activity, stability and multifunctional therapeutic applications. BACKGROUND OF THE INVENTION Turmeric (Curcuma longa) is a well-known natural source of curcuminoids and typically contains between 2 and 9 wt% curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Cyclocurcumin is a structurally modified compound formed by intramolecular cyclization of curcumin and is present in natural turmeric extracts only in negligible amounts (usually less than 1 wt%). It exhibits distinctive physicochemical and biological properties, including enhanced chemical stability, photosensitivity, antioxidant activity, and neuroprotective potential. However, the limited natural availability and instability of conventional curcuminoid compositions restrict their broader pharmaceutical and nutraceutical applications. Conventional curcumin-based formulations exhibit rapid degradation, low bioavailability, and limited functional diversity. There is a need for a cyclocurcumin-enriched formulation, complemented by stabilizing and synergistic components, to enhance therapeutic efficacy, improve oxidative stability, and enable multifunctional applications in the biomedical and pharmaceutical fields. Turmeric (Curcuma longa) has long been recognized as a valuable natural source of biologically active compounds, particularly curcuminoids such as curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Curcumin has been the most intensively studied due to its broad spectrum of pharmacological activities, including anti-inflammatory, antioxidant, antimicrobial, and anticancer effects. Despite its therapeutic potential, however, curcumin has significant physicochemical and pharmacokinetic limitations, such as low water solubility, rapid metabolic degradation, and low systemic bioavailability. These limitations have led to the exploration of structurally modified derivatives, including cyclocurcumin, which is produced by intramolecular cyclization of curcumin and exhibits different molecular behavior and improved stability under certain conditions. Cyclocurcumin occurs naturally, but is present in turmeric only in extremely low concentrations, typically less than 1% of the total curcuminoid content. Its unique structure confers beneficial properties, including increased resistance to oxidative degradation, photoresponsiveness, and enhanced interaction with biological targets such as proteins involved in neurodegenerative processes. These properties have sparked interest in fields such as photopharmacology, neuroprotection, and targeted therapeutic delivery. However, the practical application of cyclocurcumin remains limited due to challenges in its extraction, isolation, and stabilization in usable formulations. The common methods for obtaining cyclocurcumin are mainly based on direct extraction from turmeric or the chemical conversion of isolated curcumin to cyclocurcumin via acid-catalyzed cyclization reactions. Direct extraction methods, such as solvent extraction with ethanol, methanol, or acetone followed by chromatographic separation, are inefficient due to the extremely low natural abundance of cyclocurcumin. These methods require large quantities of raw material and time-consuming purification processes, resulting in low yields and poor scalability. Furthermore, the presence of multiple curcuminoids and other secondary plant metabolites complicates isolation and often leads to impure fractions with inconsistent composition. Several chemical synthesis methods have been proposed to improve the yield of cyclocurcumin. These typically involve the conversion of curcumin in the presence of strong acids such as trifluoroacetic acid in organic solvents such as benzene under controlled conditions. While such methods can increase the yield to some extent, they have several drawbacks, including the use of hazardous reagents, long reaction times, light sensitivity, and the need for strict environmental controls to prevent degradation or unwanted side reactions. Furthermore, the resulting cyclocurcumin often requires complex purification via chromatographic techniques, further increasing production costs and complexity. Another class of existing solutions involves the formulation of curcumin-based compounds with various excipients, carriers, or enhancers to improve stability and bioavailability. These include liposomal formulations, polymeric nanoparticles, micelles, and cyclodextrin inclusion complexes. While these approaches have demonstrated some improvement in curcumin release, they do not address the intrinsic limitations of curcumin's chemical instability and do not exploit the specific advantages of cyclocurcumin. Furthermore, many of these release systems are associated with complex manufacturing processes, high production costs, and potential issues related to toxicity or regulatory approval, particularly when using synthetic polymers or surfactants. In the field of cyclocurcumin formulation, very few strategies exist, and these often focus solely on synthesis rather than integration into a stable and effective composition. Cyclocurcumin is known for its photoresponsive behavior and undergoes reversible structural changes upon exposure to light. While this property is advantageous for applications such as light-controlled drug release and molecular switching processes, it also presents challenges regarding storage stability and formulation. Existing solutions do not adequately address the need for controlled stabilization of cyclocurcumin while preserving its functional properties. Another significant drawback of existing curcuminoid-based systems is the lack of synergistic optimization between active ingredients and excipients. Conventional formulations often contain curcumin as the primary active ingredient without considering the role of complementary molecules that can enhance its activity, stability, or absorption. For example, while bioavailability enhancers such as piperine are sometimes used, their concentrations are not optimized in combination with structurally modified derivatives like cyclocurcumin. Similarly, antioxidant stabilizers are not systematically added to protect sensitive compounds from oxidative degradation, resulting in reduced shelf life and inconsistent therapeutic efficacy. Furthermore, current technologies do not adequately meet the need for multifunctional formulations capable of simultaneously exerting anti-inflammatory, antioxidant, antimicrobial, and neuroprotective effects. Most available formulations are targeted at a single therapeutic objective, limiting their broader applicability. Additionally, standardized formulations with defined quantitative proportions of active ingredients and excipients are lacking, leading to variations in efficacy and reproducibility. Industrial scalability remains a major challenge for existing solutions. Extraction and synthesis processes are often energy-intensive, require specialized equipment, and involve multiple steps that cannot be readily transferred to mass production. Furthermore, the use of toxic solvents and reagents complicates regulatory compliance and environmental sustainability. Therefore, there is a need for a formulation that not only contains significant amounts of cyclocurcumin but also overcomes the limitations of existing extraction, synthesis, and formulation processes. Therefore, there is a clear need for an improved cyclocurcumin-based formulation that offers greater stability, better bioavailability, and synergistic therapeutic effects, while also being suitable for scalable production and practical application. Such a formulation should overcome the limitations of low natural availability, instability, inefficient extraction, and the lack of optimized formulation strategies, thereby enabling the effective use of cyclocurcumin in pharmaceutical, nutraceutical, and biomedical applications. SUMMARY OF THE INVENTION The present invention relates to a cyclocurcumin-based composition containing a defined proportion of cyclocurcumin as well as selected stabilizers, bioavailability enhancers, and secondary phytochemicals, and exhibiting improved antioxidant, anti-inflammatory, neuroprotective, and antimicrobial properties. The composition is formulated to ensure increased chemical stability, controlled reactivity under the influence of light, and improved physiological tolerability. In one embodiment, the composition comprises cyclocurcumin at a concentration of 15 to 45 wt% of the total composition, curcumin residual fraction at a concentration of 5 to 20 wt%, a natural antioxidant stabilizer selected from ascorbic acid or tocopherol at a concentration of 2 to 10 wt%, and a bioavailability enhancer such as piperine at a concentration of 0.5 to 5 wt%. The composition further includes a pharmaceutically acceptable carrier or excipient at a concentration of 30 to 70 wt% to improve formulation stability and administration. The main objective of the present invention is to provide a cyclocurcumin-based composition with a significantly increased cyclocurcumin concentration and defined proportions of complementary components in order to achieve improved therapeutic efficacy and stability. Another objective of the invention is to provide a composition that overcomes the limitations associated with the low natural availability and inefficient extraction of cyclocurcumin by incorporating it in a significantly enriched and usable form. Another objective of the invention is to provide a composition that exhibits improved chemical stability by incorporating suitable antioxidant stabilizers that protect cyclocurcumin and related curcuminoids from oxidative degradation and environmental stress. Another objective of the invention is to provide a composition with improved bioavailability by including absorption-enhancing agents that enable improved systemic uptake and prolonged residence time of the active ingredients. Another objective of the invention is to provide a multifunctional composition capable of achieving combined anti-inflammatory, antioxidant, antimicrobial, neuroprotective and cardioprotective effects. Another objective of the invention is to provide a composition that retains the light-sensitive properties of cyclocurcumin while ensuring controlled stability during storage and use. Another objective of the invention is to provide a composition comprising a carrier system that enables uniform dispersion, controlled release and improved delivery of the active ingredients. Another objective of the invention is to provide a composition that is suitable for large-scale production and involves less dependence on hazardous reagents and complex processing steps. Another objective of the invention is to provide a composition with consistent and reproducible performance by using defined quantitative proportions of the components. Another objective of the invention is to provide a versatile composition suitable for applications in pharmaceuticals, nutraceuticals and the development of advanced materials, including photosensitive therapeutic systems. BRIEF DESCRIPTION OF THE DRAWING These and other features, aspects and advantages of the present invention will be better understood if the following detailed description is read with reference to the accompanying drawing, in which the same symbols represent the same parts: Fig. 1 shows a block diagram of a system for the synthesis and stabilization of a cyclocurcumin-based composition. Furthermore, those skilled in the art will recognize that the elements in the drawing are simplified and not necessarily drawn to scale. For example, the flowcharts illustrate the process by highlighting the main steps to facilitate understanding of the present disclosure. With regard to the construction of the device, one or more components may be represented in the drawing by conventional symbols. The drawing may show only those specific details relevant to understanding the embodiments of the present disclosure, so as not to clutter the drawing with details that are already apparent to those skilled in the art from the description contained herein. DETAILED DESCRIPTION OF THE INVENTION To facilitate understanding of the principles of the invention, reference is made below to the embodiment shown in the drawing, which is described using specific terms. It is understood, however, that this does not limit the scope of protection of the invention. Rather, modifications and further developments of the depicted system, as well as further applications of the inventive principles shown therein, are conceivable, insofar as they would normally occur to a person skilled in the art in the field of the invention. It will be clear to those skilled in the art that the foregoing general description and the following detailed description are exemplary and explanatory of the invention and are not to be understood as a limitation of it. References to “an aspect”, “another aspect”, or similar phrases in this description mean that a particular feature, structure, or property described in connection with the embodiment is included in at least one embodiment of the present disclosure. Therefore, phrases such as “in one embodiment”, “in another embodiment”, and similar expressions in this description may, but do not necessarily, all refer to the same embodiment. The terms "includes," "comprehensive," or similar expressions denote non-exclusive inclusion. Thus, a procedure or method containing a list of steps does not only include those steps but may also include further steps not explicitly listed or inherent in the procedure or method. Likewise, the statement "includes..." for one or more devices, subsystems, elements, structures, or components, without further limitations, does not preclude the existence of other devices, subsystems, elements, structures, or components. Unless otherwise defined, all technical and scientific terms used herein have the same meanings generally known to those skilled in the art in the field to which this invention belongs. The systems, methods, and examples described herein serve only for illustration and are not to be understood as limiting. Embodiments of the present disclosure are described in detail below with reference to the attached drawing. In one embodiment, the present invention describes a cyclocurcumin-based composition comprising: cyclocurcumin in an amount of 25 to 40 wt.% of the total composition; one or more residual curcuminoids, including curcumin and demethoxycurcumin, in a combined amount of 8 to 18 wt.%; an antioxidant stabilizer selected from ascorbic acid, tocopherol or a combination thereof, in an amount of 3 to 8 wt.%; a bioavailability enhancer, including piperine, in an amount of 1 to 3 wt.%; and a pharmaceutically acceptable carrier in an amount of 40 to 60 wt.%. In one embodiment, cyclocurcumin is present in a weight percentage of 30%, the remaining curcuminoids in a weight percentage of 12%, the antioxidant stabilizer in a weight percentage of 5%, the bioavailability enhancer in a weight percentage of 2%, and the pharmaceutically acceptable carrier in a weight percentage of 51%. In one embodiment, the antioxidant stabilizer comprises ascorbic acid and tocopherol in a weight ratio of 1:1 to 1:2 within the total stabilizer content. In one embodiment, the pharmaceutically acceptable carrier comprises a biodegradable matrix selected from polysaccharides, lipid-based carriers or combinations thereof in an amount of 45 to 55% by weight. In one embodiment, the composition further comprises an antimicrobial component selected from natural essential oil extracts, in an amount of 1% to 5% by weight of the total composition. In one embodiment, the cyclocurcumin and the remaining curcuminoids are present in a weight ratio of 2:1 to 4:1. In one embodiment, the bioavailability enhancer additionally comprises another alkaloid compound in combination with piperine, the total amount being in the range of 1.5 to 4 wt.%. In one embodiment, the carrier comprises a lipid-based dispersion medium configured to enable controlled release of cyclocurcumin. In one embodiment, the composition is configured to exhibit increased oxidation stability and a reduced degradation rate under ambient conditions, which is due to the antioxidant stabilizer present in an amount of 3 to 8 wt.%. Fig. 1 shows a block diagram of a system for the synthesis of cyclocurcumin, consisting of: a material container 102 for receiving turmeric-based starting material; an extraction vessel 104 for receiving an organic solvent for obtaining a curcuminoid extract; a separation column 106 with a silica-based stationary phase for isolating curcumin; a reaction vessel 108 with an acid-resistant chamber for receiving the isolated curcumin together with an organic solvent and an acid catalyst to facilitate cyclization to cyclocurcumin; a purification column 110 for separating cyclocurcumin from reaction byproducts; and an analytical detection device 112 with spectroscopic instruments for confirming the identity and purity of cyclocurcumin. The system is configured to produce cyclocurcumin suitable for incorporation into a composition containing cyclocurcumin in an amount of 25 to 40% by weight. The present invention discloses a bioactive composition with the following focus: Cyclocurcumin is the main active ingredient. It is present in a highly concentrated form, with the concentration in a preferred embodiment being between 25 and 40 wt.%, thus significantly exceeding naturally occurring values. The composition also contains other curcuminoids, including curcumin and demethoxycurcumin, which together are present in an amount of 8 to 18 wt.% and contribute to synergistic therapeutic effects. To improve oxidative stability and prevent degradation of the active ingredients, the composition contains a stabilizing antioxidant component, preferably ascorbic acid, tocopherol, or a combination thereof, in a concentration of 3 to 8% by weight. This stabilizing component neutralizes reactive oxygen species and maintains the structural integrity of cyclocurcumin during storage and use. To improve the systemic absorption and efficacy of the preparation, a bioavailability-enhancing agent is added. This agent, selected from piperine or analogous alkaloids, is present at a concentration of 1 to 3% by weight. The addition of this agent increases permeability and reduces the metabolic degradation of cyclocurcumin in biological systems. The composition also includes a carrier matrix of pharmaceutically compatible excipients such as polysaccharides, lipid-based carriers, or biodegradable polymer matrices at a concentration of 40 to 60% by weight. The carrier matrix ensures uniform distribution, controlled release, and improved release properties of the active ingredients. Optionally, antimicrobial additives such as natural essential oil extracts can be added to the composition in an amount of 1 to 5 percent by weight, thereby achieving additional preservative and antimicrobial properties. The synergistic interaction of cyclocurcumin, residual curcuminoids, antioxidant stabilizers, and bioavailability enhancers results in a composition with improved therapeutic efficacy compared to conventional curcumin-based formulations. This composition is characterized by increased resistance to chemical degradation, enhanced free radical scavenging activity, and increased efficacy in reducing inflammatory mediators and oxidative stress. The developed cyclocurcumin-based composition was experimentally evaluated to investigate the synergistic interaction of the components and to demonstrate improved technical efficacy compared to conventional curcumin formulations. In vitro studies and investigations in simulated biological environments were conducted under standardized test conditions. In a representative antioxidant test based on DPPH radical scavenging activity, the composition with 30 wt% cyclocurcumin, 12 wt% residual curcuminoids, 5 wt% antioxidant stabilizer, and 2 wt% bioavailability enhancer showed a radical scavenging activity of 91.6% at a concentration of 50 µg / ml. A control formulation with an equivalent total amount of curcuminoids without cyclocurcumin enrichment showed a radical scavenging activity of 68.4% under identical conditions. The observed increase of approximately23% indicates a significant synergistic improvement attributable to the combined presence of cyclocurcumin and stabilizing components. For further evaluation, an in vitro inflammation model based on the inhibition of cyclooxygenase-2 (COX-2) enzyme activity was used. The described composition showed an inhibition of 78.2% at a concentration of 40 µg / ml, compared to 54.7% for a standard formulation with pure curcumin. The enhanced inhibition is attributed to the cooperative interaction between cyclocurcumin and the remaining curcuminoids, as well as to the stabilizing effect of the antioxidant component, which protects the active molecular structures under oxidative conditions. Furthermore, a cellular oxidative stress model with induced reactive oxygen species (ROS) production in cultured neuronal cells showed a 65.3% reduction in ROS levels after treatment with the composition, while the comparator formulation achieved only a 41.8% reduction. This confirms the improved neuroprotective potential. Bioavailability was investigated using a simulated gastrointestinal diffusion model. The formulation containing 2 wt% piperine showed an absorption efficiency of 72.5% across a semipermeable membrane over a 6-hour period, compared to 38.9% absorption without the bioavailability enhancer. This near-twofold increase confirms the functional contribution of the enhancer to facilitating the transport of cyclocurcumin and associated components. Stability studies under accelerated conditions at 40 °C and 75% relative humidity over 30 days revealed that the formulation retained 88.7% of its original cyclocurcumin content, while an unstabilized formulation retained only 61.2%. This demonstrates a significant improvement in resistance to degradation. The antimicrobial efficacy was investigated against representative bacterial strains. The formulation showed an inhibition zone of 18.6 mm against Escherichia coli and 16.9 mm against Staphylococcus aureus, compared to 11.2 mm and 10.5 mm, respectively, for the control formulation. This increased activity is attributed to the combined antimicrobial properties of cyclocurcumin and excipients, resulting in a broader and more effective inhibitory profile. Furthermore, the controlled release behavior, investigated in a buffer medium, demonstrated a sustained release of cyclocurcumin over a period of 12 hours with a cumulative release of approximately 76%, thus ensuring a prolonged therapeutic effect. The experimental results demonstrate that the composition delivers superior results with regard to various functional parameters, including antioxidant capacity, anti-inflammatory activity, bioavailability, stability, and antimicrobial efficacy. The quantitative improvements observed in these studies demonstrate a synergistic effect based on the specific combination and ratio of the components, thus confirming the technological advancement and efficacy of the described composition compared to existing formulations. The system for synthesizing cyclocurcumin comprises several structurally and functionally matched hardware components, each configured to perform a specific transformation or separation operation required to obtain cyclocurcumin in purified and usable form. The material container is a physical storage unit for receiving and storing turmeric raw material in solid or semi-solid form. It is made of inert materials such as stainless steel or food-grade polymer and is dimensioned to allow for the filling of large quantities and the controlled unloading of the raw material into downstream components. It protects the raw material from environmental influences, moisture, and mechanical damage before further processing. The extraction vessel is a closed reaction chamber made of solvent-resistant material, designed for use with an organic solvent such as ethanol or an equivalent medium. The vessel incorporates temperature control and stirring devices to ensure efficient contact between the turmeric-derived material and the solvent. This component facilitates the dissolution and transfer of curcuminoids from the raw matrix into the solvent phase, thus producing a curcuminoid-rich extract. The separation column is a vertically oriented, cylindrical structure filled with a silica-based stationary phase and configured for chromatographic separation. The column includes inlet and outlet channels, flow regulators, and fraction collection interfaces. This component enables the selective isolation of curcumin from the curcuminoid extract based on its different adsorption and elution properties, thus providing a purified precursor required for subsequent cyclization. The reaction vessel is a closed chamber made of acid-resistant material such as borosilicate glass-coated steel or fluoropolymer-coated metal, designed to withstand contact with acidic reagents and organic solvents. The vessel incorporates sealing devices to maintain a controlled internal environment and features for maintaining ambient or regulated temperature conditions. Within this chamber, isolated curcumin undergoes cyclization in the presence of an acid catalyst and a solvent, structurally transforming it into cyclocurcumin. The purification column is structurally similar to the separation column, but is specifically designed for the removal of reaction byproducts and unreacted intermediates from the cyclized mixture. It consists of a fixed bed of stationary phase material and is equipped with controlled flow paths and collection outlets. This component ensures the isolation of cyclocurcumin with a high degree of purity, suitable for incorporation into formulations. The analytical detection setup comprises physically integrated spectroscopic instruments, including UV / VIS spectrometers, nuclear magnetic resonance spectrometers, or comparable detection hardware. These instruments are configured to receive samples from the purification stage and generate spectra corresponding to the molecular structure and composition. The setup ensures verification of the identity, structural integrity, and purity of the manufactured cyclocurcumin. The coordinated interaction of these components enables the continuous or batch conversion of turmeric-based material into purified cyclocurcumin. Each hardware element contributes to a specific step of the material handling, extraction, separation, conversion, purification, and verification process. The system is thus configured as an integrated physical unit that produces cyclocurcumin in a form suitable for subsequent incorporation into defined formulations. The described system consists exclusively of physical apparatus elements for material handling, chemical processing, separation, and verification. Each component is manufactured as a structural unit from industrially suitable materials that withstand the mechanical, thermal, and chemical conditions encountered during operation. The material hopper, extraction vessel, reaction vessel, and columns are designed as closed chambers with defined geometries, inlet and outlet channels, sealing surfaces, and support structures that enable controlled mass transfer and retention. The separation and purification columns include fixed beds, flow control valves, and collection surfaces that physically guide and separate the components through interaction with stationary phases. The reaction vessel features acid-resistant linings, pressure-resistant walls, and temperature control to maintain the required reaction environment.The analytical detection setup comprises spectroscopic instruments with optical beam paths, detectors, and sample interfaces that interact with the processed material to generate measurable results. All components operate through mechanical, chemical, and physical interactions with liquids, solids, and reagents, forming an integrated instrumentation designed for the synthesis and purification of cyclocurcumin without the use of abstract or non-physical constructs. The drawing and the preceding description illustrate embodiments. Those skilled in the art will recognize that one or more of the described elements can be combined to form a single functional element. Alternatively, certain elements can be divided into several functional elements. Elements of one embodiment can be added to another. For example, the process flows described here can be modified and are not limited to the manner described herein. Furthermore, the actions of a flowchart need not be performed in the sequence shown; nor do all actions necessarily need to be carried out. Actions that do not depend on other actions can be performed in parallel with the other actions. The scope of protection of the embodiments is in no way limited by these specific examples. Numerous variations, whether explicitly stated in the description or not, such as...Differences in structure, dimensions, and materials are possible. The scope of protection of the embodiments is at least as comprehensive as described by the following claims. The advantages, other benefits, and problem solutions have been described above with reference to specific embodiments. However, the advantages, benefits, problem solutions, and any components that can effect or enhance an advantage, benefit, or solution are not to be construed as critical, necessary, or essential features or components of the claims. REFERENCES 100 A system for the synthesis and stabilization of a cyclocurcumin-based composition. 102 Material container 104 Extraction vessel 106 Separation column 108 Reaction vessel 110 Purification column 112 Analytical detection setup

Claims

A cyclocurcumin-based composition comprising: cyclocurcumin in an amount of 25 to 40% by weight of the total composition; one or more residual curcuminoids, including curcumin and demethoxycurcumin, in a total amount of 8 to 18% by weight; an antioxidant stabilizer selected from ascorbic acid, tocopherol, or a combination thereof in an amount of 3 to 8% by weight; a bioavailability enhancer containing piperine in an amount of 1 to 3% by weight; and a pharmaceutically acceptable excipient in an amount of 40 to 60% by weight. Composition according to claim 1, wherein cyclocurcumin is present in an amount of 30 wt. %, the remaining curcuminoids in an amount of 12 wt. %, the antioxidant stabilizer in an amount of 5 wt. %, the bioavailability enhancer in an amount of 2 wt. %, and the pharmaceutically acceptable carrier in an amount of 51 wt. %, are present. Composition according to claim 1, wherein the antioxidant stabilizer comprises ascorbic acid and tocopherol in a weight ratio of 1:1 to 1:2 within the total stabilizer content. Composition according to claim 1, wherein the pharmaceutically acceptable carrier comprises a biodegradable matrix selected from polysaccharides, lipid-based carriers or combinations thereof in an amount of 45 to 55% by weight. Composition according to claim 1, further comprising an antimicrobial component selected from natural essential oil extracts, in an amount of 1 wt.% to 5 wt.% of the total composition. Composition according to claim 1, wherein the cyclocurcumin and the remaining curcuminoids are present in a weight ratio of 2:1 to 4:

1. Composition according to claim 1, wherein the bioavailability enhancer further comprises another alkaloid compound in combination with piperine, the total amount of which is in the range of 1.5 to 4 wt.%. Composition according to claim 1, wherein the carrier comprises a lipid-based dispersion medium configured to enable controlled release of cyclocurcumin. Composition according to claim 1, wherein the composition is configured to have increased oxidation stability and a reduced degradation rate under ambient conditions due to the antioxidant stabilizer present in an amount of 3 to 8 wt.%. A system for the synthesis of cyclocurcumin, comprising: a material container designed to receive raw material derived from turmeric; an extraction vessel designed to receive an organic solvent for obtaining a curcuminoid extract; a separation column packed with a silica-based stationary phase and configured for the isolation of curcumin; a reaction vessel with an acid-resistant chamber for receiving the isolated curcumin together with an organic solvent and an acid catalyst to facilitate cyclization to cyclocurcumin; a purification column configured to separate cyclocurcumin from reaction byproducts;and an analytical detection arrangement consisting of spectroscopic instruments for confirming the identity and purity of cyclocurcumin, wherein the system is configured to produce cyclocurcumin suitable for incorporation into a composition containing cyclocurcumin in an amount of 25 to 40 wt.%.

Images